AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: VAK694 placebo
Drug: QAX576
Drug: QAX576 placebo
Drug: VAK694

First Posted Date: 2012-04-02

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT01568762

Locations: 🇺🇸
Novartis Investigative Site, Raleigh, North Carolina, United States

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: BAF312

First Posted Date: 2012-03-29

Last Posted Date: 2020-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT01565902

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo
Drug: NVA237

First Posted Date: 2012-03-29

Last Posted Date: 2014-08-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT01566604

Locations: 🇵🇭
Novartis Investigative Site, Quezon City, Philippines

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Phase 2

Terminated

Conditions: Pre-eclampsia

Interventions: Drug: Placebo
Drug: RLX030

First Posted Date: 2012-03-29

Last Posted Date: 2015-11-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT01566630

Locations: 🇮🇹
Novartis Investigative Site, Modena, MO, Italy

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma of the Lung and Thymus

Interventions: Drug: Pasireotide LAR
Drug: Pasireotide LAR and Everolimus Combination
Drug: Everolimus

First Posted Date: 2012-03-27

Last Posted Date: 2021-04-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT01563354

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

Phase 2

Terminated

Conditions: Atherosclerotic Coronary Vascular Disease

Interventions: Drug: Ranolazine 500 mg

First Posted Date: 2012-03-23

Last Posted Date: 2021-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01562041

Locations: 🇺🇸
Novartis Investigative Site, New York, New York, United States

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: LCQ908

First Posted Date: 2012-03-20

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT01558323

Locations: 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Phase 4

Completed

Conditions: Primary Myelofibrosis (PMF)
Post Polycythaemia Myelofibrosis (PPV MF)
Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Interventions: Drug: INC424

First Posted Date: 2012-03-20

Last Posted Date: 2015-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01558739

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Phase 3

Completed

Conditions: Moderate to Severe Plaque-type Psoriasis

Interventions: Drug: secukinumab 150 mg
Drug: secukinumab 300 mg
Drug: placebo

First Posted Date: 2012-03-15

Last Posted Date: 2018-08-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 177

Registration Number: NCT01555125

Locations: 🇩🇪
Novartis Investigative Site, Osnabrueck, Germany

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Salmeterol

First Posted Date: 2012-03-15

Last Posted Date: 2015-04-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 581

Registration Number: NCT01555138

Locations: 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom

Home Terms & Conditions Privacy Policy